Method for improving autologous transplantation
First Claim
1. A method for autologous hematopoietic cell transplantation in a patient receiving cytoreductive therapy, comprising:
- a. removing hematopoietic progenitor cells from the patient prior to cytoreductive therapy;
b. expanding the hematopoietic progenitor cells ex vivo with(1) a growth factor comprising granulocyte macrophage-colony stimulating factor (GM-CSF) combined with interleukin-3 (IL-3), or a GM-CSF/IL-3 fusion protein, and(2) one or more growth factors selected from the group consisting of steel factor (SF), interleukin-1 (IL-1) and granulocyte-colony stimulating factor (G-CSF) and combinations thereof,to provide a cellular preparation comprising an expanded population of hematopoietic progenitor cells; and
c. administering the cellular preparation to the patient following cytoreductive therapy.
1 Assignment
0 Petitions
Accused Products
Abstract
There is disclosed a method for autologous hematopoietic cell transplantation of patients receiving cytoreductive therapy, comprising: (1) obtaining hematopoietic progenitor cells from bone marrow or peripheral blood from a patient prior to cytoreductive therapy; (2) expanding the hematopoietic progenitor cells ex vivo with an ex vivo growth factor selected from the group consisting of interleukin-3 (IL-3), steel factor (SF), granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 (IL-1), GM-CSF/IL-3 fusion proteins and combinations thereof, to provide a cellular preparation comprising an expanded population of progenitor cells; and (3) administering the cellular preparation to the patient concurrently with or follwoing cytoreductive therapy. The inventive method optionally comprising a preliminary treatment with a recruitment growth factor to recruit hematopoietic progenitor cells into peripheral blood and a subsequent treatment with an engraftment growth factor to facilitate engraftment and proliferation of hematopoietic progenitor cells administered in the cellular preparation. The invention further provides a hematopoietic progenitor cell expansion media composition comprising cell media, an ex vivo growth factor, and autologous serum.
375 Citations
17 Claims
-
1. A method for autologous hematopoietic cell transplantation in a patient receiving cytoreductive therapy, comprising:
-
a. removing hematopoietic progenitor cells from the patient prior to cytoreductive therapy; b. expanding the hematopoietic progenitor cells ex vivo with (1) a growth factor comprising granulocyte macrophage-colony stimulating factor (GM-CSF) combined with interleukin-3 (IL-3), or a GM-CSF/IL-3 fusion protein, and (2) one or more growth factors selected from the group consisting of steel factor (SF), interleukin-1 (IL-1) and granulocyte-colony stimulating factor (G-CSF) and combinations thereof, to provide a cellular preparation comprising an expanded population of hematopoietic progenitor cells; and c. administering the cellular preparation to the patient following cytoreductive therapy. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
Specification